NCT06553547
4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs
Completed
PHASE2Ages 6–11InterventionalTreatmentArdelyx
~72 participants
Updated 2026-08-19 on ClinicalTrials.gov
What's tested:TenapanorPlacebo
At a glance
Recruiting sites
0 of 20 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Average weekly SBM (week 4)
Measured over 4 weeks
Conditions
Where it's being run
20 sites across 13 statesTexas5
Florida4
Arkansas1
Connecticut1
Illinois1
Minnesota1
Nebraska1
New York1
Study leadership
- Jocelyn Tabora · STUDY_DIRECTOR · Ardelyx
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Average weekly SBM (week 4)4 weeks
Change from baseline in average weekly SBM frequency in Week 4